INS and Parkinson disease: Moreover, the intranasal treatment with a low dose of insulin in a rat model of Parkinson’s disease, after a 6-OHDA-induced lesion, lasting for 14 days determined a significant decrease in the 6-OHDA-induced motor dysfunction and dopaminergic cell death [21].